The Board at its meeting held today, May 14, 2026, had declared Interim Dividend of INR.4.00 (200%) per equity share for the FY 2025-26 and fixed the Record date as May 30, 2026.
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.5 pts more than Nifty Smallcap 250 and 10.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Caplin Point Laboratories declared an interim dividend of INR 4.00 (200%) per equity share of face value INR 2 each for FY 2025-26. The record date for determining shareholder eligibility is May 30, 2026. For FY26, consolidated revenue grew 13.2% YoY to ₹2,303 Crores, while PAT increased 20.1% to ₹650 Crores. US market revenue surged 28.7% to ₹471 Crores. The company maintains strong liquidity with ₹1,471 Crores in free cash reserves and ₹2,726 Crores in liquid assets. The standalone PAT for FY26 stood at ₹396.58 Crores. Auditors issued unmodified opinions on both standalone and consolidated financial statements.
The 200% interim dividend signals strong cash generation and confidence in business performance. Shareholders on record as of May 30, 2026 will receive ₹4 per share. The robust 20% PAT growth and expanding US business are positive indicators for investors.